

IMMUNOTHERAPY BRIDGE
Naples, December 4th-5th, 2024

SCIENTIFIC RATIONAL

Over the last years, an extensive research has improved our understanding of tumor immunology and enabled the development of novel treatments that can harness the patient's immune system and prevent immune escape.

Through numerous clinical trials and real-world experience, a large amount of evidence of the potential for long-term survival with immunotherapy agents has been accumulated in various types of malignancy, starting from melanoma to extend to other tumors.

The results of these studies have also highlighted a number of recurring observations with immunology agents, including their potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The clinical success of immune checkpoint blockade with anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 and anti-programmed death (PD)-1/PD-ligand (L)1 inhibitor in melanoma and other cancers has encouraged increasing development of other immunotherapies, particularly monoclonal antibodies with other immune targets, adoptive cell transfer and vaccines. It has been estimated that there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways. Study results have highlighted a number of recurring observations, including the immunotherapy potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The successes of the immune-oncology is strongly correlated with the immune system ability of "memory" and adaptability, to improve the time of survival and without selecting resistant form of tumoral cells. Another advantage is that the efficacy of immunotherapy drugs does not seem to be particularly influenced by histology and mutations.

First session of the congress will be jointly organized with the Society for ImmunoTherapy of Cancer (SITC).

Hence, the state of the art of immunotherapy from the clinical point of view in various types of malignancies, the Immunotherapy beyond T cells and also the novel platforms and approaches for immune monitoring will be exhaustively discussed.

Then the "Great Debate" sessions, where counterpoint views from leading experts on specific controversial clinical issues will be presented and discussed from different points of view.

Conclusions will be drawn after the last session on Neo-Adjuvant therapies in different types of cancer.

SCIENTIFIC PROGRAM

**Speakers to be confirmed*

*** not CME accreditation*

DAY 1

Wednesday, Dec 4th

9.50 AM Introduction and Objectives, *Paolo A. Ascierto*

SITC SESSION

TIL Advancements: CAR-T and TILs

Chairpersons: *Leisha A Emens, Stephanie L. Goff*

- 10.00 AM Overview on Cell Therapy and Enhancements for CAR T-cell activity, *Avery D Posey*
- 10.20 AM Q&A
- 10.25 AM Targeting transcription factors to augment CAR T cell fitness, *Evan Weber*
- 10.45 AM Q&A
- 10.50 AM CAR-T Therapy, *Renier Brentjens*
- 11.10 AM Q&A
- 11.15 AM TIL for melanoma: the time is now, *Stephanie L. Goff*
- 11.35 AM Q&A
- 11.40 AM The best of SITC 2024, *Paolo A. Ascierto*

12.00 PM CME LECTURE – Immunotherapy on solid tumors

12.30 PM CME SYMPOSIUM – Combination Strategies

1.20 PM Lunch**

GREAT DEBATE

Chairpersons: *Paolo A. Ascierto, Leisha A. Emens, Bernard A. Fox, Igor Puzanov*

- 2.15 PM Should we continue to add something to checkpoint inhibitors or we need to change strategy? *Hussein Tawbi vs Omid Hamid*
- 2.40 PM No role for first line chemo-immuno VS vegf/immuno first line
David Carbone vs Toni Choeri
- 3.05 PM ADCs VS Bispecific, *Leisha A. Emens vs Samir Khleif*

SESSION 2

IMMUNOTHERAPY BEYOND T CELLS AND IMMUNOTHERAPY BEYOND CLASSICAL T CELLS

Chairpersons: *Alfredo Budillon, Luigi Buonaguro*

- 3.30 PM B cells, *Chrystal Paulos*
- 3.45 PM NK Cells, *Avery D Posey*
- 4.00 PM Myeloid Cells, *Jennifer Guerriero*
- 4.15 PM Neutrophil Cells, *Brahm Segal*
- 4.30 PM Macrophages as tools and targets in cancer therapy *Cecilia Garlanda*
- 4.45 PM Armored CAR-T Cells, *Renier Brentjens*
- 5.00 PM Gamma Delta T Cells, *Adrian Hayday**
- 5.15 PM DISCUSSION Round Table

SESSION 3 – IMMUNE MONITORING: NOVEL PLATFORMS AND APPROACHES

Chairpersons: *Elizabeth M. Burton, Lisa H. Butterfield*

- 5.45 PM Landscape/overview of trends in biomarker proposals – CIMAC/SITC, *Holden Maecker*
- 6.00 PM Integrating data across biomarker platforms, *Christine N. Spencer*
- 6.15 PM Leveraging AI to integrate image based analyses, *Lacey Padron*
- 6.30 PM DISCUSSION Round Table

DAY 2

Thursday, Dec 5th

9.15 AM **Welcome coffee****

SESSION 4 - ORGAN SPECIFIC IMMUNE RESPONSE

Chairpersons: *Omid Hamid, Sandro Pignata*

9.30 AM Pancreatic Cancer, *Renato Ostuni*

9.40 AM Lung cancer; *Alessandro Morabito*

9.50 AM Renal cancer, *Tony Choueiri*

10.00 AM GU cancer, *Akash Patnaik*

10.10 AM GI cancer, *Gregory B. Lesinski*

10.20 AM Endometrial Cancer, *Emese Zsiros*

10.30 AM Ovarian Cancer, *Kunle Odunsi*

10.40 AM Head & Neck, *Robert Ferris*

11.00 AM DISCUSSION Round Table

GREAT DEBATE

Chairpersons: *Paolo A. Ascierto, Leisha A. Emens, Bernard A. Fox, Igor Puzanov*

11.40 AM Should we do combination immunotherapy trials with drugs that lack single agent activity? Yes or no, *Bernard A. Fox vs Igor Puzanov*

12.05 PM Pre-treatment predictive biomarkers: INF g vs. Immunoscore vs. multiplex IF/next-generation spatial biology, *Christian Blank vs Jerome Galon vs Janice Taube*

12.40 PM Do we need vaccines? Yes or no, *Pawel Kalinski vs Stephen Schoenberger*

1.05 PM **Lunch****

2.00 PM **CME SYMPOSIUM – Non-Melanoma Skin Cancers**

SESSION 5 - NEOADJUVANT THERAPY ACROSS CANCERS

Chairpersons: *Paolo A. Ascierto, Elizabeth M. Burton*

2.50 PM Breast, *Leisha A. Emens*

3.05 PM Lung, *Tina Cascone*

3.20 PM CRC, *TBD*

3.35 PM Melanoma, *Christian Blank*

3.50 PM Non Melanoma Skin Cancers, *Neil Gross*

4.05 PM Potentially translational insights across cancers, *TBD*

4.20 PM Pan tumor path response assessment, *TBD*

4.35 PM DISCUSSION Round Table

5.05 PM **Conclusion**

PRESIDENCY

Paolo A. Ascierto

Director of Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute IRCCS Fondazione “G. Pascale”, Naples, Italy

Leisha A. Emens

Senior Vice President Translational Research, Ankyra Therapeutics, Incorporated, Boston, MA, US;
President of Society for Immunotherapy of Cancer (SITC)

Bernard A. Fox

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Center Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

Igor Puzanov

Judith and Sanford Lipsey Chair in Clinical Cancer Research; Senior Vice President, Clinical Investigation Chief, Division of Melanoma, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

FACULTY

Ascierto	Paolo Antonio	Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Department	National Cancer Institute "Fondazione G. Pascale"	Napoli
Blank	Christian	Medical Oncology and Research Group Leader Tumor Immunology	Netherlands Cancer Institute	Amsterdam, The Netherlands
Brentjens	Renier	Deputy Director and Chair of the Department of Medicine	Roswell Park Comprehensive Cancer Center	Buffalo, NY, US
Budillon	Alfredo	Scientific Director	National Cancer Institute "Fondazione G. Pascale"	Napoli
Buonaguro	Luigi	Director, Innovative Immunological Models Unit	National Cancer Institute "Fondazione G. Pascale"	Napoli
Burton	Elizabeth M.	Director, Research Planning & Development, Surgical Oncology	The University of Texas MD Anderson Cancer Center	Houston, TX, US
Butterfield	Lisa	Adjunct Professor Microbiology and Immunology	University of California, San Francisco;	San Francisco, CA, US
Carbone	David	Professor of internal medicine; co-leader of the Translational Therapeutics Program at the OSUCC.	The Ohio State University	Columbus, OH, USA
Cascone	Tina	Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine	The University of Texas MD Anderson Cancer Center	Houston, TX, US
Choueiri	Toni	Director of the Lank Center for Genitourinary (GU) Oncology; co-leader of the Kidney Cancer Program; Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School	Dana-Farber Cancer Institute (DFCI)	Boston, Massachusetts, US
Emens	Leisha A.	Senior Vice President Translational Research, President of Society for Immunotherapy of Cancer (SITC)	Ankyra Therapeutics, Incorporated	Boston, MA, US;

Ferris	Robert L.	Professor and Chief of Head and Neck Oncologic Surgery in the Department of Otolaryngology and Immunology	University of Pittsburgh Cancer Institute	Pittsburgh, PA, US
Fox	Bernard	Chief of Laboratory of Molecular and Tumor Immunology	Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Center	Portland, OR, US
Galon	Jerome	Research Director, National Institute of Health and Medical Research (INSERM), Director, Integrative Cancer Immunology Team,	Cordeliers Research Center	Parigi, Francia
Garlanda	Cecilia	Professore Associato di Patologia Clinica	Humanitas University; Humanitas Research Hospital	Milano
Goff	Stephanie L	Senior Staff of the Surgery Branch	Center for Cancer Research National Cancer Institute	Bethesda, MD, US
Gross	Neil D.	Professor, Department of Head and Neck Surgery, Division of Surgery	MD Anderson Cancer Center	Houston, Texas, US
Guerriero	Jennifer	Assistant Professor of Surgery	Brigham and Women's Hospital	Boston, MA, US
Hamid	Omid	Director of the Melanoma Center and Phase I Immuno-Oncology Program	Angeles Clinic and Research Institute	Los Angeles, CA, US
Hayday	Adrian	Professor and chair in the Department of Immunobiology; group leader	King's College London	London, UK
Kalinski	Pawel	SVP, Team Science; Chair, Department of Immunology; Professor of Oncology & Chief, Translational Immuno-Oncology	Roswell Park Comprehensive Cancer Center	Buffalo, New York, US
Khleif	Samir N.	Director of the Center for Immunology and Immunotherapy, Director of the Loop Immuno-Oncology Laboratory, Lombardi Comprehensive Cancer Center	Georgetown University Medical School	Washington, DC, US
Lesinski	Gregory B	Professor, Vice Chair for Basic Research, Department of Hematology & Medical Oncology Associate Director for Basic Research Co-Director, Translational GI Malignancy Program	Winship Cancer Institute of Emory University	Atlanta, GA, US
Maecker	Holden	Professor (research) of Microbiology and immunology	Stanford University	Stanford, CA,US
Morabito	Alessandro	Director of Thoracic Medical Oncology	National Cancer Institute "Fondazione G. Pascale"	Napoli
Odunsi	Kunle	Professor of Medicine Director of Comprehensive Cancer Research Center Dean for Oncology, Biological Sciences Division	University of Chicago Medicine Comprehensive Cancer Center	Chicago, IL, US

Ostuni	Renato	Group Leader, Unità di Genomica del Sistema Immunitario Innato	San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget)	Milano
Padron	Lacey	Vice President, Informatics	Parker Institute for Cancer Immunotherapy	San Francisco, CA, US
Patnaik	Akash	Medical oncologist and physician-scientist, leading a translational research program in clinical and experimental therapeutics	University of Chicago, Department of Medicine	Chicago, IL, US
Paulos	Chrystal	Director of translational research in cutaneous malignancies	Winship Cancer Institute of Emory University	Atlanta, GA, US
Pignata	Sandro	Direttore SC Oncologia Clinica Sperimentale Uro-Ginecologica	Istituto Nazionale dei Tumori IRCCS Fondazione Pascale	Napoli
Posey	Avery D	Assistant professor of Systems Pharmacology and Translational Therapeutics	University of Pennsylvania	Philadelphia, PA, US
Puzanov	Igor	Professor of Medicine and Oncology, Director Early Phase Clinical Trials Program, Co-Leader Experimental Therapeutics Program, Chief Melanoma Section	Department of Medicine, Roswell Park Cancer Institute	Buffalo, NY, US
Schoenberger	Stephen	Professor, La Jolla Institute for Immunology Co-Director,	Center for Autoimmunity and Inflammation, Center for Cancer Immunotherapy, Center for Vaccine Innovation, La Jolla Institute	San Diego, CA, US
Segal	Brahm	Chair of the Dept. of Internal Medicine and Chief of Infectious Diseases, Professor of Medicine	Roswell Park Comprehensive Cancer Center, Jacobs School of Medicine & Biomedical Sciences	Buffalo, NY, US
Spencer	Christine N.	Omic consulting, medical oncologist	Parker Institute for Cancer Immunotherapy	San Francisco, CA, US
Taube	Janis	Director, Division of Dermatopathology	The Johns Hopkins Hospital	Baltimore, MD, US
Tawbi	Hussein	Professor, Deputy Chair and Director of Personalized Cancer Therapy, Department of Melanoma Medical Oncology, Division of Cancer Medicine; Co-Director, MD Anderson Brain Metastasis Clinic	The University of Texas MD Anderson Cancer Center	Houston, TX, US
Weber	Evan	Center for Childhood Cancer Research	Children's Hospital of Philadelphia	Philadelphia, PA, US
Zsiros	Emese	Chair in Gynecologic Oncology	Roswell Park Comprehensive Cancer Center	Buffalo, NY, US